NRCNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
NRC HEALTH
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$20.47+0.32 (+1.59%)
Close on Oct 19, 2026
- Market cap
- $450.52M
- P/E (TTM)
- 0.4
- Dividend yield
- 2.54%
NRC HEALTH revenue by segment
By business segment
By product or service
By region
| Revenue | Q4 24 | Q1 24 | Q4 23 | Q3 23 | Q2 23 | Q1 23 | Q4 22 | Q3 22 | Q2 22 | Q1 22 | Q4 21 | Q3 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | $35.31M | $38.00M | $37.95M | $36.16M | $36.47M | $38.14M | $37.69M | $37.09M | $37.85M | $37.66M | $37.11M | – | – |
| Canada | – | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $203.00K | $591.00K | $635.00K | $661.00K | – | – |
From the segment and revenue-disaggregation notes of Nrc Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.